Moderate to severe chronic liver disease can be predicted with the use of diffusion-weighted MRI
(DWI), according to a recent study conducted by researchers at New York University Medical Center
in New York, NY.

　Due to the increased incidence of chronic hepatitis in the United States, particularly hepatitis C,
there is a strong need for non-invasive methods to replace or supplement liver biopsy, which is
relatively invasive and limited by interobserver variability and sampling error, said Bachir Taouli,
MD, lead author of the study. DWI appears promising in that purpose, although it needs validation
in larger series, he said.

　The study included 23 patients with chronic hepatitis and 7 volunteers. The researchers compared
apparent diffusion coefficients (ADCs) or the quantification of water diffusion in a tissue between
patients who had stage 2 or greater versus stage 1 or less fibrosis and stage 3 or greater versus stage
2 or less fibrosis. In liver fibrosis and cirrhosis, decreased ADC (i.e. restricted water diffusion) is
possibly related to increased collagen deposition and decreased perfusion. The study showed that
hepatic ADC was a significant predictor of stage 2 or greater and stage 3 or greater liver fibrosis.

　At this point, this is an experimental method that needs to be tested in a larger series. It should also
be compared with other methods such as FibroTest (a score based on a combination of basic serum
markers) or FibroScan (an ultrasound based method to measure liver stiffness) in order to be validated,
said Dr. Taouli. However, diffusion imaging does show potential for decreasing the number of biopsies
and decreasing the number of antifibrogenic drug trials, he said.

　We did not expect to have such good results in terms of detection of significant fibrosis, partly
because this is an investigational study and we did not have any prior experience with such application,
said Dr. Taouli.